Excimer Laser With Topical Agents in Psoriasis Vulgaris

• Status: Not yet recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Psoriasis is a chronic, immune-mediated disease that affects approximately 2% of the population. The development and exacerbation of psoriasis involve an interaction between multiple genetic and environmental risk factors.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Tazarotene

Criteria

Inclusion Criteria:

1. Age: ≥18 years.

2. Pattern: Patients with chronic plaque psoriasis not exceeding 10% of the body surface area.

Exclusion Criteria:

1. History of retinoid use either topical or systemic in the previous 16 weeks, phototherapy or topical psoriasis treatment within the last 4 weeks.

2. Allergy to any ingredients of tretinoin or betamethasone drugs.

3. Renal, hepatic disease, cardiovascular , Immunosuppressive therapy, endocrine and blood disease or mental illness.

4. Pregnancy, breast-feeding or women planning to become pregnant within 3 months.

5. Psoriasis exceeding 10% of body surface area or other severe types of psoriasis requiring systemic treatment.

6. Patients with other diseases and requiring treatment that would affect the study